ClinicalTrials.Veeva

Menu

Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression

H

Hillerod Hospital, Denmark

Status

Terminated

Conditions

Major Depression

Treatments

Drug: Pindolol and venlafaxin

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00159146
version 5

Details and patient eligibility

About

This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Full description

Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded formulation in combination with Venlafaxine compared to placebo Pindolol and Venlafaxine for a duration of 19 days.

Effect is measured by the Hamilton Depression rating Scale and the Preskorn Scale (self-rating).

Enrollment

31 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major depression

Exclusion criteria

  • Allergy towards pindolol, venlafaxine or other tablet constituents
  • Liver or kidney impairment
  • Diabetics
  • Age below 18 years
  • Severe cardiac disease
  • Asthma.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

31 participants in 2 patient groups, including a placebo group

A
Active Comparator group
Description:
Venlafaxine and pindolol
Treatment:
Drug: Pindolol and venlafaxin
B
Placebo Comparator group
Description:
Venlafaxin and placebo
Treatment:
Drug: Pindolol and venlafaxin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems